Karen Carey

Learn More
OBJECTIVE To test the effect of three questions (what are my options? what are the benefits and harms? and how likely are these?), on information provided by physicians about treatment options. METHODS We used a cross-over trial using two unannounced standardized patients (SPs) simulating a presentation of mild-moderate depression. One SP was assigned the(More)
OBJECTIVE To test the feasibility and assess the uptake and acceptability of implementing a consumer questions programme, AskShareKnow, to encourage consumers to use the questions '1. What are my options; 2. What are the possible benefits and harms of those options; 3. How likely are each of those benefits and harms to happen to me?' These three questions(More)
The paper describes the current position of shared decision making (SDM) within the Australian healthcare system. SDM POLICY IN AUSTRALIA: Support for SDM exists through guidelines and policy documents, and is strongly endorsed by consumer organisations; however, there is no clear overarching policy framework for SDM in Australia. TOOLS FOR SDM: There are(More)
Pyruvate carboxylase [EC 6.4.1.1] plays an important anaplerotic role in many species by catalyzing the carboxylation of pyruvate to oxaloacetate. To extend our understanding about the structure and function of pyruvate carboxylase (PC), a series of monoclonal antibodies were raised against sheep liver PC and those displaying inhibitory activity were(More)
Sandoz, the generic drugs unit of Basel’s Novartis, announced in January that it has begun a phase 2 rheumatoid arthritis trial with its own version of blockbuster monoclonal antibody (mAb) Rituxan (MabThera, rituximab). It joins Teva Pharmaceuticals, of Petach Tikva, Israel, and Spectrum Pharmaceuticals, of Irvine, California, both of whom are also working(More)